Diamyd[ ]Medical announces expanded financial support from Breakthrough T1D
Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world’s leading Type 1 Diabetes research and advocacy organization, in support of the DIAGNODE-3 Phase 3 trial to facilitate the potential submission of a regulatory filing for approval.This additional funding builds upon the existing collaboration to support the ongoing DIAGNODE-3 trial evaluating a precision medicine antigen-specific immunotherapy for autoimmune diabetes. The funding is provided through Breakthrough T1D’s Industry Discovery & Development Partnerships (